[HTML][HTML] Chronic cough: new insights and future prospects

A Morice, P Dicpinigaitis, L McGarvey… - European Respiratory …, 2021 - Eur Respiratory Soc
Chronic cough is defined in adults as a cough that lasts for≥ 8 weeks. When it proves
intractable to standard-of-care treatment, it can be referred to as refractory chronic cough …

Management of functional communication, swallowing, cough and related disorders: consensus recommendations for speech and language therapy

J Baker, C Barnett, L Cavalli, M Dietrich… - Journal of Neurology …, 2021 - jnnp.bmj.com
Communication problems (eg, dysphonia, dysfluency and language and articulation
disorders), swallowing disorders (dysphagia and globus), cough and upper airway …

[HTML][HTML] Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study

A Morice, JA Smith, L McGarvey… - European …, 2021 - Eur Respiratory Soc
Background ATP acting via P2X3 receptors is an important mediator of refractory chronic
cough (RCC). This phase 2a double-blinded crossover study assessed the safety …

[HTML][HTML] The role of transient receptor potential vanilloid 1 in common diseases of the digestive tract and the cardiovascular and respiratory system

Q Du, Q Liao, C Chen, X Yang, R Xie, J Xu - Frontiers in Physiology, 2019 - frontiersin.org
Transient receptor potential vanilloid subtype 1 (TRPV1), a member of the transient receptor
potential vanilloid (TRPV) channel family, is a nonselective cation channel that is widely …

[HTML][HTML] Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers

AJ Davenport, I Neagoe, N Bräuer, M Koch… - Scientific Reports, 2021 - nature.com
Abstract ATP-dependent P2X3 receptors play a crucial role in the sensitization of nerve
fibers and pathological pain pathways. They are also involved in pathways triggering cough …

Mechanisms and rationale for targeted therapies in refractory and unexplained chronic cough

SB Mazzone, L McGarvey - Clinical Pharmacology & …, 2021 - Wiley Online Library
Chronic cough, defined as a cough lasting> 8 weeks, is a common medical condition that
exerts a substantial physical, mental, and social burden on patients. A subset of patients with …

BLU-5937: a selective P2X3 antagonist with potent anti-tussive effect and no taste alteration

D Garceau, N Chauret - Pulmonary pharmacology & therapeutics, 2019 - Elsevier
BLU-5937 is a small molecule that was shown to be a potent, selective and non-competitive
P2X3 homotrimeric receptor antagonist. P2X3 receptors are ATP ion-gated channels located …

[HTML][HTML] The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial

C Friedrich, K Francke, SS Birring… - Respiratory …, 2023 - Springer
Background P2X3 receptor antagonists seem to have a promising potential for treating
patients with refractory chronic cough. In this double-blind, randomized, placebo-controlled …

[HTML][HTML] KAAACI evidence-based clinical practice guidelines for chronic cough in adults and children in Korea

DJ Song, WJ Song, JW Kwon, GW Kim… - Allergy, Asthma & …, 2018 - ncbi.nlm.nih.gov
Chronic cough is common in the community and causes significant morbidity. Several
factors may underlie this problem, but comorbid conditions located at sensory nerve endings …

[HTML][HTML] Is laryngeal hypersensitivity the basis of unexplained or refractory chronic cough?

KM Sundar, AC Stark, N Hu… - ERJ Open …, 2021 - Eur Respiratory Soc
Refractory chronic cough (RCC) and unexplained chronic cough (UCC) are common
problems seen in primary care and subspecialty clinics. The role of cough hypersensitivity …